The big commercial real estate firms put roughly a quarter or more of the Bay Area's life-science space as vacant this year. One of the largest lab buildings finished in the past year is on Dubuque Avenue in South San Francisco. Yet in October 2026, single-family homes in South City sold for an average of 109% of their list prices. That figure was up from 107% in October 2025, and the homes sold faster than they had a year earlier.
A lab vacancy rate measures empty square footage. It rises when developers finish buildings faster than tenants sign leases, and it rises when companies cut staff. South San Francisco has had both, and much of its lab space came onto the market all at once. The biotech cluster has lost some jobs, but most of them remain, and the people in those jobs still need somewhere to live nearby. For a buyer comparing South City with Daly City or San Bruno, that means the houses will cost about what they did last year. Any room to bargain is in condos and townhomes.
Much of the empty space is new construction
Cushman & Wakefield's Q2 2026 Bay Area life sciences report put regional vacancy at 29.0%. The same report says eight speculative ground-up projects, about 2.0 million square feet in total, were finished in the 12 months before that quarter. One of them is IQHQ's SPUR Phase I at 580 Dubuque Avenue in South San Francisco, at 330,350 square feet. "Speculative" means the developer built it before signing tenants. When that many such buildings open within one year, the vacancy rate climbs before any layoffs are counted.
Other firms measure the market differently and get lower numbers. Savills' Q3 2026 Bay Area life-science report, published October 14, put overall vacancy at 23.8%, down 0.2 percentage points from a year earlier. Colliers' Q2 2026 Peninsula R&D report, which covers a smaller area, put vacancy at 24.7%. It also said positive net absorption and leasing came mainly from life-science tenants, especially in South San Francisco. These are three methods over three slightly different areas. They agree that a lot of space sits empty. According to Colliers, much of the Peninsula's new leasing is in South City.
The layoffs are counted in the dozens and hundreds
Job cuts have happened, and the state's WARN notices list them by address. In 2026, the life-science notices filed at South San Francisco addresses include these:
- Genentech: 103 workers at 1 DNA Way, notice dated June 26.
- Cellares: 100 workers at 1100 Veterans Boulevard, dated August 21.
- Arsenal Biosciences: 58 workers at 329 Oyster Point Boulevard, dated August 31.
2025 had a longer list. It included Genentech notices for 143, 87 and 118 workers, Arsenal for 100, NGM Biopharmaceuticals for 85, Alector for 75 and Pliant Therapeutics for 69. A WARN notice is an announcement of planned cuts and does not confirm that each one took effect.
The size of the cluster puts those numbers in proportion. In a brochure the city describes as current as of spring 2024, South San Francisco counted more than 25,000 direct employees in its biotech cluster. The city's biotech page lists more than 250 biotech companies in about 12 million square feet. Regional job counts have fallen. Cushman & Wakefield's figures, based on Lightcast data, show Bay Area life-sciences employment at 104,400 at the end of Q2 2026, compared with 113,700 a quarter earlier. That is a Bay Area figure, though. South City alone has not lost enough jobs to empty a neighborhood, and the money behind its companies kept coming. The same Q2 report says the region's two largest venture deals that quarter went to South San Francisco companies, NewLimit at $435 million and Cellares at $327 million.
Companies are still moving in
The lease records from 2026 point to steady demand. In March, CoStar reported that Neuralink leased all 144,200 square feet of 499 Forbes Boulevard, a building InterVenn had left after canceling its lease in 2023. In May, Bisnow reported that Olema Pharmaceuticals leased about 38,000 square feet at 355–369 Oyster Point Boulevard for a new headquarters, with just over 13,100 of those square feet held for future growth.
Cushman & Wakefield's deal tables for the first half of 2026 list more new South City leases. Neurona Therapeutics took 32,974 square feet at 260 Littlefield and Soleil Labs took 32,000 at 233 East Grand. Trex Bio took 33,780 at 269 Grand, MapLight Therapeutics took 33,482 at 490–494 Forbes, and Plasmidsaurus took 19,452 at 2 Tower Place. In September, CoStar reported a 10,000-square-foot sublease by the contract research firm Quantall at 343 Oyster Point.
The largest employer is also planning ahead. On September 3, 2026, the South San Francisco Planning Commission approved the entitlements for Genentech's gRED Center, voting 5–0 with two commissioners absent. SF YIMBY described the project as seven structures with about 1.25 million square feet, and construction is expected between 2027 and 2033. The Registry reported in February that the wider campus modernization is a planned $5 billion effort that would nearly double the campus to 9 million square feet. An employer that is planning a decade of construction on its home campus expects to keep its workforce in South City.
What October's sales say about South City houses
That steady base of jobs shows up in SAMCAR's October 2026 single-family table. South San Francisco had 25 sales at a $1,300,000 median, with an average of 18 days on market and 1.1 months of inventory. A year earlier, in October 2025, the median was $1,280,000, homes averaged 24 days on market, and they sold at 107% of list. Inventory did rise, from 14 active listings to 20, so October buyers had a few more homes to choose from. The homes still sold quickly and above asking.
The medians alone make South City look like Daly City. Daly City's October median was $1,305,000, almost the same, and San Bruno's was $1,670,000. Price per square foot shows something different. South City's median was $1,024 per square foot. San Bruno's was $1,060 and Daly City's was $842. South City's lower median comes mostly from smaller houses. The average South City house sold in October was 1,484 square feet, compared with 1,581 in San Bruno and 1,666 in Daly City. Space costs about as much in South City as it does next door in San Bruno, and the homes are smaller.
There is earlier local evidence that biotech jobs have tracked housing costs. The San Mateo Daily Journal reported that a city report found South City's shift from industrial to biotech jobs coincided with an 80% rise in median gross rent from 2012 to 2022. That finding is a correlation, not proof that one caused the other. Housing costs rose as the cluster grew. Because the cluster is still largely in place, there is little reason to expect house prices to fall back.
Where a buyer has more room
Condos and townhomes are a different market. In SAMCAR's October 2026 table for common interest developments, which groups condos and townhomes together, South San Francisco had a $779,000 median and sold at 101% of list after an average of 38 days on market. The city had 2.7 months of inventory, more than twice the single-family figure. Only four units sold in October, so the 16% rise from October 2025's $672,500 median says more about which four units closed than about prices. The steadier numbers are days on market, which averaged 38 in both Octobers, and active listings, which rose from 12 to 17. A buyer looking at a South City condo has more time to decide and less pressure to bid far over asking than someone bidding on a house a few blocks away. For context, the county as a whole also showed 2.7 months of condo and townhome inventory and sales at 101% of list in October.
More townhomes are in the pipeline. The Gateway, a 70-townhome project by Newlife Investments at 500 Railroad Avenue near the Caltrain station, has 42 two-bedroom and 28 three-bedroom homes planned, ranging from 1,250 to 2,200 square feet. The San Mateo Daily Journal reported that the City Council voted unanimously to support the project and that the developer expected to break ground in early 2026. The city's development map, updated October 17, still lists it as Railroad Townhomes. In a city where four condos and townhomes sold in October, seventy new townhomes would be a large addition to what buyers have to choose from.
Quick answers
Should I wait for South City house prices to fall as biotech cools? October's sales do not point that way. Compared with October 2025, the median stayed near $1.3 million, days on market fell from 24 to 18, and the sale-to-list ratio rose from 107% to 109%.
Is South City a cheaper version of San Bruno? In October 2026, the two cities' medians per square foot were $1,024 and $1,060. Most of the difference in median price came from house size.
What would change the picture? The things to watch are large South City layoff notices from big employers, the Genentech gRED Center moving toward construction, and new townhome supply such as The Gateway reaching the market.
If you're weighing a South City house against a condo, or South San Francisco against its neighbors, I'm glad to go through this October's sales with you, one block at a time. You can start with our South San Francisco neighborhood page or ask for a home valuation if you own here now. When you're ready, Suzanne Garcia is a call away. Let's connect.